Johnson & Johnson

2nd Quarter 2020 Results

2nd Quarter 2020 Sales

$18.3B Worldwide Decreased **(10.8)%**

Excluding acquisitions/ divestitures on an operational basis — Worldwide Decreased **(8.8)%***

Diluted Earnings Per Share		Adjusted Diluted Earnings Per Share*	
$1.36	Decreased (34.6)%	$1.67	Decreased (35.3)%





Alex Gorsky
Chairman and
Chief Executive Officer
Johnson & Johnson

"Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment. Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives. We are bringing together our best minds, our global footprint and our sophisticated supply chain technology to deliver on our commitment to provide the vaccine on a not-for-profit basis for emergency pandemic use, globally. We know the need is urgent, and every day we commit to doing our part to find a solution for the global good."

$3.3 Billion

Worldwide Consumer Health Sales

Consumer Health worldwide reported sales decreased (7.0)% or (3.6)% operationally[1]. Primary offsets to decline:

TYLENOL, LISTERINE, ZARBEE'S NATURALS, Pepcid, OGX beauty pure and simple

$10.8 Billion

Worldwide Pharmaceutical Sales

Pharmaceutical worldwide reported sales increased 2.1% or 3.9% operationally[1]. Primary operational drivers:

Stelara (ustekinumab), DARZALEX (daratumumab), imbruvica (ibrutinib) 140mg capsules, Tremfya (guselkumab), Erleada (apalutamide) 60 mg tablets, Uptravi selexipag tablets 200-1600 mcg, INVEGA SUSTENNA paliperidone palmitate 39mg, 78mg, 117mg, 156mg, 234mg, Symtuza darunavir/cobicistat/emtricitabine/ tenofovir alafenamide tablets 800mg/150mg/200mg/10mg, Opsumit macitentan, Juluca dolutegravir 50 mg/ rilpivirine 25 mg tablets

$4.3 Billion

Worldwide Medical Devices Sales

Medical Devices worldwide reported sales decreased (33.9)% or (32.7)% operationally[1]. Primary operational drivers:

- Surgical Vision
- Knees
- Hips
- Spine
- Contact Lens
- Wound Closure
- Endocutters
- Electrophysiology

Note: values may have been rounded

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson's earnings release issued on July 16, 2020, available at http://www.investor.jnj.com/sales-earnings.cfm.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

[1]Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on July 16, 2020, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.